The global nicotine replacement therapy market was valued at $2,659.0 million in 2021, and is projected to reach $5,955.95 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.
Nicotine replacement therapy is a medically approved way to treat people with tobacco use disorder by taking nicotine by means other than tobacco. The nicotine replacement products such as nicotine gum and patches work by providing nicotine to the body to decrease the withdrawal symptoms experienced when smoking is stopped and as a substitute oral activity to reduce the urge to smoke.
The increase in prevalence of tobacco cancer owing to high cigarette smoking rate in urban cities drives the growth of the nicotine replacement therapy market. In addition, there is high tobacco chewing rate in rural area in both males and females, which further increases the risk of cancer. For instance, according to the report of American Cancer Society (ACS) published in October 2020, tobacco use remains the leading preventable cause of death in the U. S., accounting for about 1 in 5 deaths each year. From the same source, smoking causes about 20% of all cancers and about 30% of all cancer deaths in the U. S.
Furthermore, rise in awareness about cancer and increase in initiatives by respective governments to promote awareness about the risk associated with tobacco consumption contributes to the growth of the market. In addition, various non-government and non-profit organizations operate to promote awareness about hazardous effects of smoking, which further boosts the demand for nicotine replacement therapy.
The rise in demand for smoking cessation aids such as nicotine gums and patches owing to social media awareness campaigns and government awareness programs motivating people to quit smoking, provides ample opportunities for the market growth. Nicotine replacement therapy reduces the withdrawal symptoms and helps to control the drive to smoke tobacco.
Moreover, the increase in R&D activities for development of advanced nicotine replacement therapy, product approvals, and novel product launches by key players boost the market growth. The patient centric products development such as nicotine gums and lozenges propels the demand for nicotine replacement products. However, strict government regulations and ban of e cigarettes in many countries may hinder the growth of the market.
The nicotine replacement therapy market is segmented based on product, sales channel, location, and region. By product, the market is classified into gums, lozenges, patches, and others. Depending on sales channel, it is divided into online and offline. As per location, it is categorized into hospitals & deaddiction centers and home. The hospitals & deaddiction centers is further divided into male and female. The home segment is further bifurcated into male and female. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Cipla Limited, Fertin Pharma Ltd., GlaxoSmithKline plc, Johnson & Johnson Inc., Lucy Goods, Inc., Pfizer Inc., PL Developments, Rubicon Research Pvt. Ltd., Sparsha Pharma International Pvt. Ltd., and Zydus Cadila.
Nicotine replacement therapy is a medically approved way to treat people with tobacco use disorder by taking nicotine by means other than tobacco. The nicotine replacement products such as nicotine gum and patches work by providing nicotine to the body to decrease the withdrawal symptoms experienced when smoking is stopped and as a substitute oral activity to reduce the urge to smoke.
The increase in prevalence of tobacco cancer owing to high cigarette smoking rate in urban cities drives the growth of the nicotine replacement therapy market. In addition, there is high tobacco chewing rate in rural area in both males and females, which further increases the risk of cancer. For instance, according to the report of American Cancer Society (ACS) published in October 2020, tobacco use remains the leading preventable cause of death in the U. S., accounting for about 1 in 5 deaths each year. From the same source, smoking causes about 20% of all cancers and about 30% of all cancer deaths in the U. S.
Furthermore, rise in awareness about cancer and increase in initiatives by respective governments to promote awareness about the risk associated with tobacco consumption contributes to the growth of the market. In addition, various non-government and non-profit organizations operate to promote awareness about hazardous effects of smoking, which further boosts the demand for nicotine replacement therapy.
The rise in demand for smoking cessation aids such as nicotine gums and patches owing to social media awareness campaigns and government awareness programs motivating people to quit smoking, provides ample opportunities for the market growth. Nicotine replacement therapy reduces the withdrawal symptoms and helps to control the drive to smoke tobacco.
Moreover, the increase in R&D activities for development of advanced nicotine replacement therapy, product approvals, and novel product launches by key players boost the market growth. The patient centric products development such as nicotine gums and lozenges propels the demand for nicotine replacement products. However, strict government regulations and ban of e cigarettes in many countries may hinder the growth of the market.
The nicotine replacement therapy market is segmented based on product, sales channel, location, and region. By product, the market is classified into gums, lozenges, patches, and others. Depending on sales channel, it is divided into online and offline. As per location, it is categorized into hospitals & deaddiction centers and home. The hospitals & deaddiction centers is further divided into male and female. The home segment is further bifurcated into male and female. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Cipla Limited, Fertin Pharma Ltd., GlaxoSmithKline plc, Johnson & Johnson Inc., Lucy Goods, Inc., Pfizer Inc., PL Developments, Rubicon Research Pvt. Ltd., Sparsha Pharma International Pvt. Ltd., and Zydus Cadila.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nicotine replacement therapy market analysis from 2021 to 2031 to identify the prevailing nicotine replacement therapy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nicotine replacement therapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global nicotine replacement therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Gums
- Lozenges
- Patches
- Others
By Sales Channel
- Online
- Offline
By Location
- Hospitals and Deaddiction centers
- Gender
- Male
- Female
- Home
- Gender
- Male
- Female
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Cipla Ltd
- Fertin Pharma Limited
- GlaxoSmithKline plc
- Johnson & Johnson Inc
- Lucy Goods Inc
- Pfizer Inc
- PL Developments
- Rubicon Research Pvt Ltd
- Sparsha Pharma International Pvt. Ltd.
- Zydus Cadila
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2. Gums
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Lozenges
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Patches
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5. Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
CHAPTER 5: NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2. Online
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Offline
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION
6.1 Overview
6.1.1 Market size and forecast
6.2. Hospitals and Deaddiction centers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.2.4 Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
6.2.4.1 Male Market size and forecast, by region
6.2.4.2 Female Market size and forecast, by region
6.3. Home
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.3.4 Home Nicotine Replacement Therapy Market by Gender
6.3.4.1 Male Market size and forecast, by region
6.3.4.2 Female Market size and forecast, by region
CHAPTER 7: NICOTINE REPLACEMENT THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Sales Channel
7.2.4 North America Market size and forecast, by Location
7.2.4.1 North America Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.2.4.2 North America Home Nicotine Replacement Therapy Market by Gender
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Sales Channel
7.2.5.1.4 Market size and forecast, by Location
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Sales Channel
7.2.5.2.4 Market size and forecast, by Location
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Sales Channel
7.2.5.3.4 Market size and forecast, by Location
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Sales Channel
7.3.4 Europe Market size and forecast, by Location
7.3.4.1 Europe Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.3.4.2 Europe Home Nicotine Replacement Therapy Market by Gender
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Sales Channel
7.3.5.1.4 Market size and forecast, by Location
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Sales Channel
7.3.5.2.4 Market size and forecast, by Location
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Sales Channel
7.3.5.3.4 Market size and forecast, by Location
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Sales Channel
7.3.5.4.4 Market size and forecast, by Location
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Sales Channel
7.3.5.5.4 Market size and forecast, by Location
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Sales Channel
7.3.5.6.4 Market size and forecast, by Location
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Sales Channel
7.4.4 Asia-Pacific Market size and forecast, by Location
7.4.4.1 Asia-Pacific Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.4.4.2 Asia-Pacific Home Nicotine Replacement Therapy Market by Gender
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Sales Channel
7.4.5.1.4 Market size and forecast, by Location
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Sales Channel
7.4.5.2.4 Market size and forecast, by Location
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Sales Channel
7.4.5.3.4 Market size and forecast, by Location
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Sales Channel
7.4.5.4.4 Market size and forecast, by Location
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Sales Channel
7.4.5.5.4 Market size and forecast, by Location
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Sales Channel
7.4.5.6.4 Market size and forecast, by Location
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Sales Channel
7.5.4 LAMEA Market size and forecast, by Location
7.5.4.1 LAMEA Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.5.4.2 LAMEA Home Nicotine Replacement Therapy Market by Gender
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Sales Channel
7.5.5.1.4 Market size and forecast, by Location
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Sales Channel
7.5.5.2.4 Market size and forecast, by Location
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Sales Channel
7.5.5.3.4 Market size and forecast, by Location
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Sales Channel
7.5.5.4.4 Market size and forecast, by Location
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1 Cipla Ltd
9.1.1 Company overview
9.1.2 Key Executives
9.1.3 Company snapshot
9.1.4 Operating business segments
9.1.5 Product portfolio
9.1.6 Business performance
9.1.7 Key strategic moves and developments
9.2 Fertin Pharma Limited
9.2.1 Company overview
9.2.2 Key Executives
9.2.3 Company snapshot
9.2.4 Operating business segments
9.2.5 Product portfolio
9.2.6 Business performance
9.2.7 Key strategic moves and developments
9.3 GlaxoSmithKline plc
9.3.1 Company overview
9.3.2 Key Executives
9.3.3 Company snapshot
9.3.4 Operating business segments
9.3.5 Product portfolio
9.3.6 Business performance
9.3.7 Key strategic moves and developments
9.4 Johnson & Johnson Inc
9.4.1 Company overview
9.4.2 Key Executives
9.4.3 Company snapshot
9.4.4 Operating business segments
9.4.5 Product portfolio
9.4.6 Business performance
9.4.7 Key strategic moves and developments
9.5 Lucy Goods Inc
9.5.1 Company overview
9.5.2 Key Executives
9.5.3 Company snapshot
9.5.4 Operating business segments
9.5.5 Product portfolio
9.5.6 Business performance
9.5.7 Key strategic moves and developments
9.6 Pfizer Inc
9.6.1 Company overview
9.6.2 Key Executives
9.6.3 Company snapshot
9.6.4 Operating business segments
9.6.5 Product portfolio
9.6.6 Business performance
9.6.7 Key strategic moves and developments
9.7 PL Developments
9.7.1 Company overview
9.7.2 Key Executives
9.7.3 Company snapshot
9.7.4 Operating business segments
9.7.5 Product portfolio
9.7.6 Business performance
9.7.7 Key strategic moves and developments
9.8 Rubicon Research Pvt Ltd
9.8.1 Company overview
9.8.2 Key Executives
9.8.3 Company snapshot
9.8.4 Operating business segments
9.8.5 Product portfolio
9.8.6 Business performance
9.8.7 Key strategic moves and developments
9.9 Sparsha Pharma International Pvt. Ltd.
9.9.1 Company overview
9.9.2 Key Executives
9.9.3 Company snapshot
9.9.4 Operating business segments
9.9.5 Product portfolio
9.9.6 Business performance
9.9.7 Key strategic moves and developments
9.10 Zydus Cadila
9.10.1 Company overview
9.10.2 Key Executives
9.10.3 Company snapshot
9.10.4 Operating business segments
9.10.5 Product portfolio
9.10.6 Business performance
9.10.7 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Nicotine Replacement Therapy Market,' the nicotine replacement therapy market was valued at $2.7 billion in 2021, and is estimated to reach $5.9 billion by 2031, growing at a CAGR of 8.3% from 2022 to 2031.Nicotine replacement therapy is a method or program used to support nicotine cessation. It helps to deal with withdrawal symptoms of nicotine smoking and tobacco chewing. Various products such as nicotine gums, nicotine lozenges, and nicotine patches are used as supportive aid. These products help to reduce the drive for nicotine by providing nicotine through patches or gums.
The Nicotine Replacement Therapy Market Trends such as an increase in the prevalence of cancer and respiratory disorders owing to tobacco consumption and smoking drives the growth of the nicotine replacement therapy market. For instance, in September 2020, according to World Health Organization (WHO), every year 1.9 million people die from tobacco-induced heart disease worldwide. Tobacco smoking increases the formation of plaque in blood vessels. In addition, it can cause an increase in blood pressure, heart rate, the flow of blood to the heart, and a narrowing of the arteries. Thus, owing to such harmful effects of smoking on health various governments made strict regulations such as a ban on nicotine products and heavy taxation on tobacco products. In addition, various government and non-government organizations work to promote the awareness about ill effects of tobacco on the body, further contributing to the growth of the Nicotine Replacement Therapy Industry.
Furthermore, factors that drive the growth of the nicotine replacement therapy market include an increase in healthcare expenditure, a rise in the number of key players who manufacture nicotine replacement products at affordable cost, and collaboration between manufacturers and organizations to supply nicotine cessation aids. In addition, the growth in the number of people who are willing to discontinue smoking further contributes to the growth of the Nicotine Replacement Therapy Industry.
Moreover, an increase in R&D activities for the development of advanced nicotine replacement therapy methods, new product approvals, and product launch drives the growth of the market. Furthermore, the rise in government funding for de-addiction centers and improvement in healthcare facilities in developing nations contribute to the growth of the nicotine replacement therapy market.
The nicotine replacement therapy market is segmented based on product, sales channel, location, and region.
On the basis of product, the market is classified into gums, lozenges, patches, and others. The gums segment dominated the Nicotine Replacement Therapy Market Share in 2021, and this trend is expected to continue during the Nicotine Replacement Therapy Market Forecast period, owing to the advantages of nicotine gums such as they provide an alternative chewing activity instead of chewing tobacco.
As per the sales channel, the market is divided into online and offline. The offline segment dominated the Nicotine Replacement Therapy Market size in 2021, and this trend is expected to continue during the forecast period, owing to an increase in the availability of nicotine lozenges and gums at stores and pharmacies.
Depending on location, the market is classified into hospitals & deaddiction centers, and homes. The hospitals & deaddiction centers segment dominated the Nicotine Replacement Therapy Market Size in 2021, and this trend is expected to continue during the Nicotine Replacement Therapy Market Analysis period, owing to an increase in the number of hospitals & deaddiction centers and a rise in the prevalence of tobacco-associated diseases.
Region-wise, North America accounted for a majority of the global nicotine replacement therapy market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the increase in the prevalence of smoking-associated lung diseases, well-established healthcare infrastructure, and a surge in healthcare expenditure. Asia-Pacific is anticipated to witness lucrative growth, owing to the rise in the prevalence of tobacco-associated diseases, a high population base, and the presence of key players in the region.
Key findings of the study
Based on product, the gums segment was the highest contributor to the market in 2021.By sales channel, the offline segment was the highest contributor to the market in 2021.
Depending on location, the hospitals and deaddiction centers segment was the highest contributor to the market in 2021.
Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at a significant CAGR during the forecast period.
Companies Mentioned
- Cipla Ltd.
- Fertin Pharma Limited
- GlaxoSmithKline PLC
- Johnson & Johnson Inc.
- Lucy Goods Inc.
- Pfizer Inc.
- Pl Developments
- Rubicon Research Pvt Ltd.
- Sparsha Pharma International Pvt. Ltd.
- Zydus Cadila
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 290 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 2659 million |
| Forecasted Market Value ( USD | $ 5955.95 million |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
